title: Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis.
abstract: BACKGROUND
  Fibrosing cholestatic hepatitis (FCH) is an uncommon but potentially fatal complication of recurrent hepatitis C (HCV) in liver transplant recipients.
  
  
  METHODS
  We matched the treatment outcomes of 10 liver transplant recipients who developed FCH with those of 10 recipients with recurrent HCV without FCH treated with sofosbuvir and ribavirin.
  
  
  RESULTS
  Baseline mean alanine transaminase, aspartate transaminase, alkaline phosphatase, and total bilirubin were 186 U/L, 197 U/L, 243 U/L, and 6.7 mg/dL, respectively, in the FCH recipients and 82 U/L, 60 U/L, 110 U/L, and 0.99 mg/dL, respectively, in non-FCH recipients. The sustained viral response in FCH and non-FCH recipients was 40% and 80%, respectively. One-yr patient and graft survival rates were 90% and 80%, respectively, in FCH recipients, and 100% in non-FCH recipients. Seven FCH and six non-FCH recipients were treated for anemia with blood transfusion and/or erythropoietin growth factors.
  
  
  CONCLUSIONS
  Our results suggest that the use of sofosbuvir and ribavirin is effective and tolerable in liver transplant recipients treated for recurrent FCH. There is a trend of lower sustained viral response, patient survival, and graft survival in the FCH recipients.
authors.affiliation: Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.|Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA.
authors.forename: Sammy
authors.initials: S
authors.lastname: Saab
authors.affiliation: Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA.
authors.forename: Melissa
authors.initials: M
authors.lastname: Jimenez
authors.affiliation: Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA.
authors.forename: Sherona
authors.initials: S
authors.lastname: Bau
authors.affiliation: Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
authors.forename: Tyralee
authors.initials: T
authors.lastname: Goo
authors.affiliation: Department of Biostatistics, University of California at Los Angeles, Los Angeles, CA, USA.
authors.forename: Difan
authors.initials: D
authors.lastname: Zhao
authors.affiliation: Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.|Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA.
authors.forename: Francisco
authors.initials: F
authors.lastname: Durazo
authors.affiliation: Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.|Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Han
authors.affiliation: Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.|Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA.
authors.forename: Mohammed
authors.initials: M
authors.lastname: El Kabany
authors.affiliation: Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA.
authors.forename: Fady
authors.initials: F
authors.lastname: Kaldas
authors.affiliation: Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA.|Liver Center, Huntington Medical Research Institutes, Pasadena, CA, USA.
authors.forename: Myron J
authors.initials: MJ
authors.lastname: Tong
authors.affiliation: Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA.
authors.forename: Ronald W
authors.initials: RW
authors.lastname: Busuttil
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D002780:Cholestasis, Intrahepatic / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D016031:Liver Transplantation; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy* / Q000401:mortality; D012008:Recurrence; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D000069474:Sofosbuvir
keywords: antiviral therapy; fibrosing cholestatic hepatitis; hepatitis C; liver transplant; patient survival